Newsbenzinga
Serina Therapeutics Completes Sentinel Dosing In Group 1 Of Its Phase 1b Study Of SER-252 To Treat Parkinson's Disease
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…